CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 623 enrolled
Drug / intervention
Tavilermide ophthalmic solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03925727
NCT03925727Phase 3Completed
CompareCT.gov

Multi-Center, Randomized,Double-Masked, Vehicle-Controlled Study to Assess the Safety and Efficacy Study of Tavilermide Ophthalmic Solutions for the Treatment of Dry Eye

Mimetogen Pharmaceuticals USA, Inc.·interventional·Posted Apr 24, 2019·Updated Apr 5, 2023

In Brief

A Phase 3 clinical trial evaluating Tavilermide ophthalmic solution and Placebo for Keratoconjunctivitis Sicca and Dry Eye. Completed, enrolled 623 participants across 22 sites.

Detailed Summary

The purpose of this study is to assess the safety and efficacy of 5% tavilermide and 1% tavilermide ophthalmic solutions compared with placebo ophthalmic solution in treating the signs and symptoms of dry eye.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKeratoconjunctivitis Sicca, Dry Eye
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedApr 24, 2019
Enrollment StartMar 28, 2019
Primary CompletionJun 11, 2020
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 7.2 years ago

Interventions

Tavilermide ophthalmic solutiondrug

BID topical dosing

Placeboother

BID topical dosing